Cargando…

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

BACKGROUND: Factors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain to be elucidated. METHODS: Forty allo-HCT recipients were included in a study of immunization with BNT162b2 mRNA vaccine at days 0 and 21. Binding anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canti, Lorenzo, Humblet-Baron, Stéphanie, Desombere, Isabelle, Neumann, Julika, Pannus, Pieter, Heyndrickx, Leo, Henry, Aurélie, Servais, Sophie, Willems, Evelyne, Ehx, Grégory, Goriely, Stanislas, Seidel, Laurence, Michiels, Johan, Willems, Betty, Liston, Adrian, Ariën, Kevin K., Beguin, Yves, Goossens, Maria E., Marchant, Arnaud, Baron, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542409/ https://www.ncbi.nlm.nih.gov/pubmed/34689821 http://dx.doi.org/10.1186/s13045-021-01190-3

Ejemplares similares

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
por: Canti, Lorenzo, et al.
Publicado: (2022)

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
por: Ariën, Kevin K., et al.
Publicado: (2022)

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
por: Baron, Frédéric, et al.
Publicado: (2022)

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
por: Pannus, Pieter, et al.
Publicado: (2022)

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
por: Servais, Sophie, et al.
Publicado: (2015)

Validation of a multicolor staining to monitor (phospho)STAT5 levels in regulatory T-cell subsets
por: Ehx, Grégory, et al.
Publicado: (2015)

Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells
por: Ritacco, Caroline, et al.
Publicado: (2023)

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.
por: Goossens, Maria E., et al.
Publicado: (2021)

How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation
por: Vandenhove, Benoît, et al.
Publicado: (2020)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
por: Kemlin, Delphine, et al.
Publicado: (2023)

Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia
por: Servais, Sophie, et al.
Publicado: (2022)

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
por: Konnova, Angelina, et al.
Publicado: (2022)

Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores
por: De Voeght, Adrien, et al.
Publicado: (2022)

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults
por: Pannus, Pieter, et al.
Publicado: (2023)

Evaluation of immune suppressive mechanisms in a murine model of familial hemophagocytic lymphohistiocytosis
por: Humblet-Baron, Stéphanie, et al.
Publicado: (2011)

Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease
por: Fransolet, Gilles, et al.
Publicado: (2016)

Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice
por: Ehx, Grégory, et al.
Publicado: (2018)

CTLA4-Ig Effectively Controls Clinical Deterioration and Immune Condition in a Murine Model of Foxp3 Deficiency
por: Gerbaux, Margaux, et al.
Publicado: (2023)

Ontogeny of Myeloid Cells
por: De Kleer, Ismé, et al.
Publicado: (2014)

Models of Aire-Dependent Gene Regulation for Thymic Negative Selection
por: Danso-Abeam, Dina, et al.
Publicado: (2011)

A cross entropy test allows quantitative statistical comparison of t-SNE and UMAP representations
por: Roca, Carlos P., et al.
Publicado: (2023)

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model
por: Grégoire, Céline, et al.
Publicado: (2019)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient
por: Michiels, Yves, et al.
Publicado: (2021)

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay
por: Mariën, Joachim, et al.
Publicado: (2021)

Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease
por: Belle, Ludovic, et al.
Publicado: (2016)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society
por: Baron, Frédéric, et al.
Publicado: (2015)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Missense mutations in inositol 1,4,5-trisphosphate receptor type 3 result in leaky Ca(2+) channels and activation of store-operated Ca(2+) entry
por: Terry, Lara E., et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

HJ16 induced resistant virus displays rare natural mutation highlighting the conserved nature of this new CD4bs epitope
por: Balla-Jhagihoorsingh, Sunita S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_31ggbnjr6netsq5p3uc8qbkh6e